Acquisition builds on EVERSANA’s commitment to investing in transformative, technology-first companies to modernize commercialization.

CHICAGO and LONDON, Oct. 28, 2026 /PRNewswire/ — EVERSANA®, a global provider of modern, AI-powered commercial services for the biopharmaceutical industry, today announced the acquisition of Estima Scientific, an innovative, London-based health economics and outcomes research (HEOR) technology and services company.

A leader in artificial intelligence (AI) and automation to accelerate elements of traditional HEOR processes, Estima Scientific will integrate its specialty consulting expertise and proprietary software into EVERSANA’s market access and value & evidence solutions to help pharmaceutical companies demonstrate a drug’s clinical and economic value more efficiently and transparently to payers. Estima has developed a variety of web-based, generative-AI applications that integrate proprietary code, bringing efficiency and accuracy across economic modeling, systematic literature reviews (SLR), network meta-analysis (NMA), and more.

Estima Scientific builds on EVERSANA’s continued commitment to AI-enabled, technology-first offerings to drive accelerated commercialization for customers. EVERSANA’s AI Agency platform, launched in 2025 and expanded in August 2026, serves as the foundation for expanding the company’s AI solutions.

“Today more than ever, the pharmaceutical industry must embrace AI to transform commercialization,” said Mark Thierer, Chief Executive Officer, EVERSANA. “As we scale to serve global clients, adding best-in-class companies that embrace a technology first mindset is critical to our success. The Estima Scientific team checks every box and will seamlessly fit into our organization.”

Estima Scientific’s team, including its co-founders Tim Reason and Andy Gimblett, will join EVERSANA’s global workforce, ensuring continuity for existing clients while bringing expanded capabilities across EVERSANA. The company’s solutions have been validated by large, top-tier pharmaceutical customers and leading health technology assessment (HTA) bodies, including the National Institute for Health and Care Excellence (NICE) in the United Kingdom.

“Joining EVERSANA is an incredible milestone for Estima Scientific and a validation of the specialized technology and consulting expertise our team has built,” said Tim Reason, co-founder of Estima Scientific. “The company’s global scale and end-to-end commercial infrastructure will allow us to accelerate how pharmaceutical companies build and communicate evidence-based value to payers, helping patients gain faster access to life-changing therapies.”

Estima was founded in 2019 by Tim Reason and Andy Gimblett, following long careers in HEOR and software development. The company has built a strong base of global clients that rely on its proprietary AI-powered technology to support research studies for leading global pharmaceutical brands.

Financial details of the acquisition are not disclosed. Bourne Partners acted as exclusive financial adviser to Estima Scientific, and Wedlake Bell acted as legal adviser.

About EVERSANA®

EVERSANA® is an independent provider of modern commercialization services to the biopharmaceutical industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X.

About Estima Scientific

Estima Scientific is a London-based health economics and outcomes research (HEOR) technology and services company. By combining specialist consulting with proprietary, AI-powered software, Estima Scientific helps pharmaceutical and biotechnology companies demonstrate therapeutic value to global payers and health technology assessment bodies efficiently. To learn more, visit estima-sci.com.

Media Contact

Matt Braun
Vice President, Corporate Communications
matt.braun@eversana.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eversana-expands-global-commercialization-and-ai-powered-heor-capabilities-with-acquisition-of-uk-based-estima-scientific-302921421.html

SOURCE EVERSANA